מדינה: הממלכה המאוחדת
שפה: אנגלית
מקור: MHRA (Medicines & Healthcare Products Regulatory Agency)
Riboflavin; Thiamine hydrochloride; Pyridoxine hydrochloride; Ascorbic acid; Calcium pantothenate; Calcium levulinate; Calcium chloride dihydrate; Nicotinamide
Wallace Manufacturing Chemists Ltd
A11AA02
Riboflavin; Thiamine hydrochloride; Pyridoxine hydrochloride; Ascorbic acid; Calcium pantothenate; Calcium levulinate; Calcium chloride dihydrate; Nicotinamide
25microgram/1ml ; 100microgram/1ml ; 25microgram/1ml ; 1mg/1ml ; 25microgram/1ml ; 70mg/1ml ; 24mg/1ml ; 400microgram/1ml
Oral solution
Oral
No Controlled Drug Status
Never Valid To Prescribe As A VMP
BNF: 09100000; GTIN: 05034593027309
Calcimax Syrup _Please read this leaflet carefully before using this _ _medicine. If you have any questions or are not sure _ _about anything, ask your doctor or pharmacist. _ Calcimax Syrup has the following active ingredients in each 5ml: Calcium Levulinate 350.00 mg Calcium Chloride Dihydrate BP 120.00 mg Nicotinamide BP 2.00 mg Riboflavine BP 0.125 mg Thiamine Hydrochloride BP 0.50 mg Pyridoxine Hydrochloride BP 0.125 mg Ascorbic Acid BP 5.00 mg Calcium Pantothenate BP 0.125 mg In addition the syrup also contains the following non- active ingredients: Disodium Edetate, Sucrose, Glycine, Sodium Saccharin, Nipasept, Nipabutyl, Propylene Glycol, Glycerin, Soluble Orange Oil, Essence Morella Cherry, Burnt Sugar, Hydrochloric Acid, Purified Water Calcimax syrup is available in bottles of 150ml. Calcimax is a dietary supplement of Calcium and Vitamins B and C. The product licence holder is Wallace Manufacturing Chemists Ltd, Wallace House, 51-53 Stert Street Abingdon, Oxfordshire OX14 3JF, United Kingdom Product Licence number: PL 00400/5007R The product is manufactured for Wallace Manufacturing Chemists Ltd by Thorpe Laboratories Ltd, Enterprise Road, Mablethorpe, Lincolnshire LN12 1NB The product is intended as a supplement of Calcium and Vitamins B and C during periods of dietary need. It is not intended to treat clinical deficiencies. Do not take Calcimax Syrup if any of the following applies to you: You suffer from raised blood calcium levels You have pronounced levels of calcium in your urine You have taken an overdose of Vitamin D You suffer from tumours which remove calcium from the body You have severe kidney failure You have kidney stones You should seek medical advice before taking Calcimax Syrup if you have any kidney problems. The syrup contains sucrose and this may adversely affect dental hygiene or control of diabetes. Calcimax has propylene glycol as a preservative and hypersensitivity reactions may occur in susceptible individuals. Calcimax Syrup may react with other foods o קרא את המסמך השלם
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Calcimax Syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5ml contains:- Calcium Levulinate 350.00 mg Calcium Chloride Dihydrate BP 120.00 mg Nicotinamide BP 2.00 mg Riboflavine BP 0.125 mg Thiamine HCl BP 0.50 mg Pyridoxine HCl BP 0.125 mg Ascorbic Acid BP 5.00 mg Calcium Pantothenate BP 0.125 mg 3. PHARMACEUTICAL FORM Oral Syrup 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As a dietary supplement of Calcium and Vitamins B & C in situations of special dietary need. Not suitable for correction of deficiency states. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults and Elderly: Four 5ml spoonfuls twice or more times per day as directed by a doctor. Children: One to Two 5ml spoonfuls three times per day according to age or as directed by a doctor. 4.3 CONTRA-INDICATIONS Hypercalcaemia and severe hypercalciuria, Vitamin D overdose, decalcifying tumours, severe renal failure, renal calculi. 4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE Use with caution in patients with renal impairment. The syrup contains sucrose and this may adversely affect dental hygiene or control of diabetes. Calcimax has propylene glycol as a preservative and hypersensitivity reactions may occur in susceptible individuals. 4.5 INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION High vitamin D intake should be avoided during calcium therapy unless specially indicated. Although it is unlikely that hypercalcaemia will result from the administration of Calcimax, there is a risk of adverse digoxin effects in digitalised patients. Oral Calcium may reduce the absorption of Tetracyclines. Pyridoxine may antagonise effects of L-dopa unless the patient is receiving a peripheral Dopa-decarboxylase inhibitor. Co-administration of thiazides increases the risk of hypercalcaemia. 4.6 PREGNANCY AND LACTATION Epidemiological studies have shown no increase in the teratogenic hazard to the foetus if used in the dose recommended for usual vitamin and calcium קרא את המסמך השלם